Opus Bio

Opus Bio is a private, pre-clinical stage biotech focused on next-generation lipid nanoparticle (LNP) delivery systems for mRNA therapeutics. The company's core innovation is a novel LNP formulation engineered to bypass immune-activating pathways, thereby reducing toxicity and enabling safe chronic re-dosing or potent single-dose therapies. Spun out from UC Berkeley's Innovative Genomics Institute, Opus aims to establish a new gold standard in non-viral delivery, targeting a broad range of diseases currently limited by delivery challenges. Its technology is positioned to expand the application of mRNA beyond vaccines into chronic and genetic diseases.

Novel lipid nanoparticle (LNP) platform engineered to bypass immune-activating pathways, reducing toxicity and enabling safe chronic re-dosing or single-dose mRNA therapies. Aims for IV and subcutaneous administration.

The non-viral delivery space is highly competitive, with players like Acuitas, Genevant, and numerous startups advancing LNP technology. Opus must differentiate its immune-evasive approach and demonstrate clear advantages in potency, safety, and re-dosing capability.